Brian Rini
机构: Vanderbilt University Medical Center
每年引用次数
引用次数
引用: 82,216
H-指数: 127
I10-指数 : 564
出版物: 1,236
Emerging drugs for renal cell carcinoma
Leticia Varella , Brian I Rini
Expert Opinion on Emerging Drugs 15 ( 3) 343 -353
4
2010
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research.
Toni K Choueiri , Michael B Atkins , Ziad Bakouny , Maria I Carlo
Journal of the National Cancer Institute 113 ( 3) 234 -243
2
2021
Clinical and immunomodulatory effects of bevacizumab and low‐dose interleukin‐2 in patients with metastatic renal cell carcinoma: results from a phase II trial
Jorge A. Garcia , Tarek Mekhail , Paul Elson , Pierre Triozzi
BJUI 107 ( 4) 562 -570
15
2011
Dual VEGF/VEGFR inhibition in advanced solid malignancies: Clinical effects and pharmacodynamic biomarkers
Kriti Mittal , Henry Koon , Paul Elson , Pierre Triozzi
Cancer Biology & Therapy 15 ( 8) 975 -981
14
2014
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
Frede Donskov , M Dror Michaelson , Igor Puzanov , Mellar P Davis
British Journal of Cancer 113 ( 11) 1571 -1580
70
2015
MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
C Marcela Diaz-Montero , Frances J Mao , John Barnard , Yvonne Parker
British Journal of Cancer 115 ( 8) 920 -928
31
2016
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
Jenny J Ko , Wanling Xie , Nils Kroeger , Jae-lyun Lee
The Lancet Oncology 16 ( 3) 293 -300
196
2015
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
Brian I Rini , Bohuslav Melichar , Takeshi Ueda , Viktor Grünwald
The Lancet Oncology 14 ( 12) 1233 -1242
253
2013
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study
Lauren C Harshman , Wanling Xie , Georg A Bjarnason , Jennifer J Knox
Lancet Oncology 13 ( 9) 927 -935
97
2012
Targeted therapy for patients with renal-cell carcinoma
Brian I Rini
Lancet Oncology 12 ( 12) 1085 -1087
6
2011
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Daniel YC Heng , Wanling Xie , Meredith M Regan , Lauren C Harshman
Lancet Oncology 14 ( 2) 141 -148
898
2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Robert J Motzer , Bernard Escudier , Piotr Tomczak , Thomas E Hutson
Lancet Oncology 14 ( 6) 552 -562
494
2013
Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma.
Danielle A Murphy , Brian I Rini , Bernard Escudier , Robert J Motzer
Future Oncology 16 ( 17) 1199 -1210
1
2020
Current status and future directions of molecular markers in renal cell carcinoma.
Brian I Rini
Current Opinion in Urology 16 ( 5) 332 -336
16
2006
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Thomas Powles , Elizabeth R Plimack , Denis Soulières , Tom Waddell
Lancet Oncology 21 ( 12) 1563 -1573
33
2020
Renal cell carcinoma
W Kimryn Rathmell , Paul A Godley , Brian I Rini
Current Opinion in Oncology 17 ( 3) 261 -267
2005
Renal cell carcinoma
Brian I Rini , Steven C Campbell , W Kimryn Rathmell
Current Opinion in Oncology 18 ( 3) 289 -296
2006
Sunitinib
Brian I Rini
Expert Opinion on Pharmacotherapy 8 ( 14) 2359 -2369
2007
Sorafenib
Brian I Rini
Expert Opinion on Pharmacotherapy 7 ( 4) 453 -461
2006
Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial
Meredith M Regan , Opeyemi A Jegede , Charlene M Mantia , Thomas Powles
Clinical Cancer Research 27 ( 24) 6687 -6695
15
2021